EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. (EYPT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
eypt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for EyePoint Pharmaceuticals, Inc. (EYPT) measures how much investors pay for each dollar of the company's trailing earnings. EYPT's current PE ratio of N/A is calculated by dividing its stock price of $11.93 by its TTM earnings per share of -$3.16.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
EyePoint Pharmaceuticals, Inc.You EYPT | $1.0B | N/A | — | -$3.16 |
 Bicara Therapeutics Inc. Common Stock BCAX | $1.1B | N/A | — | -$2.52 |
 Kodiak Sciences Inc. KOD | $1.6B | N/A | — | -$4.32 |
 Kura Oncology, Inc. KURA | $776M | N/A | — | -$3.18 |
 Nurix Therapeutics, Inc. NRIX | $1.3B | N/A | — | -$3.05 |
 Prime Medicine, Inc. PRME | $553M | N/A | — | -$1.35 |
 ProKidney Corp. PROK | $605M | N/A | — | -$0.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.17 | — | |
2024-12-31 FY2024 | — | $-2.32 | — | |
2023-12-31 FY2023 | — | $-1.82 | — | |
2022-12-31 FY2022 | — | $-2.74 | — | |
2021-12-31 FY2021 | — | $-2.03 | — | |
2020-12-31 FY2020 | — | $-3.54 | — | |
2019-12-31 FY2019 | — | $-5.44 | — | |
2018-06-30 FY2018 | — | $-11.50 | — | |
2017-06-30 FY2017 | — | $-5.23 | — | |
2016-06-30 FY2016 | — | $-6.81 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for EyePoint Pharmaceuticals, Inc. (EYPT) measures how much investors pay for each dollar of the company's trailing earnings. EYPT's current PE ratio of N/A is calculated by dividing its stock price of $11.93 by its TTM earnings per share of -$3.16.
Frequently asked questions
EYPT pe ratio · 6 questionsEYPT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $11.93 and TTM EPS of -$3.16. Data sourced from Financial Modeling Prep via EYPT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · EyePoint Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08